Article information
Abstract
Darunavir (DRV) is an HIV-1 protease inhibitor that is used together with a low boosting dose of ritonavir as part of an antiretroviral therapy (ART) regimen in treatment-experienced and naïve HIVpositive patients. In naïve and experienced patients with no DRV-mutations, DRV is licensed at the dose of 800 mg plus 100 mg of ritonavir once daily. We report our results in seven ART-experienced HIV-infected patients, in whom a reduced dose of darunavir/ritonavir (600/100 mg once daily) successfully controlled viral replication
Keywords:
HIV infections
pharmacokinetics antiretroviral therapy, highly active
Full text is only aviable in PDF
References
[1.]
D. Deschamps, S. Lambert-Niclot, A.G. Marcelin, et al.
Mutation associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients.
J Antimicrob Chemother, 63 (2009), pp. 585-592
[2.]
R. Ortiz, E. DeJesus, H. Khanlou, et al.
Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1-infected patients at week 48.
AIDS, 22 (2008), pp. 1389-1397
[3.]
K. Arasteh, N. Clumeck, A. Pozniak, et al.
TMC 1147 ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: A 14-day-proof-of-principle trial.
AIDS, 19 (2005), pp. 943-947
[4.]
S. De Meyer, S. Spinoza-Guzman, T. Vangeneugden, et al.
Efficacy of once-daily darunavir/ritonavir 800/100 mg in HIVinfected, treatment-experienced patients with no resistanceassociated mutations to darunavir.
J Acquir Immune Defic Syndr, 49 (2008), pp. 179-182
[5.]
Cahn P, Fourie J, Grinsztejn B, et al. Efficacy and safety of 48 weeks of once-daily vs twice daily DRV/r in treatment-experienced HIV-1+ patients with no DRV resistance-associated mutations:the ODIN trial 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, California, February 2010. [abstr 57].
[6.]
M. Boffito, D. Miralles, A. Hill.
Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and –exeprienced patients.
HIV Clin Trials, 9 (2008), pp. 418-427
[7.]
V.A. Johnson, F. Brun-Vezinet, B. Clotet, et al.
Update of the drug resistance mutations in HIV-1: Spring 2008.
Top HIV Med, 16 (2008), pp. 62-68
[8.]
I. Dierynck, M. De Wit, E. Gustin, et al.
Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier.
J Virol, 81 (2007), pp. 13845-13851
[9.]
K. McKeage, C.M. Perry, S.J. Keam.
Darunavir: a review of its use in the management of HIV infection in Adults.
Drugs, 69 (2009), pp. 477-503
[10.]
S. De Meyer, H. Azijn, D. Surleraux, et al.
TMC 114, a novel human immunedeficiency virus type 1 protease inhbitor active against protease inhibitor-resistance viruses, including a broad range of clinical isolates.
Antimicrob Agents Chemother, 49 (2005), pp. 2314-2321
[11.]
D. Gonzalez de Requena, S. Bonora, O. Vigano, et al.
Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48-week virological response to darunavir-based salvage regimens.
J Antimicrob Chemother, 66 (2011), pp. 192-200
Copyright © 2011. Elsevier Editora Ltda.. All rights reserved
